ECP
AEON.WS

Empyrean Capital Partners’s AEON Biopharma Inc AEON.WS Stock Holding History

Empyrean Capital Partners’s Portfolio AEON.WS Stock Details AEON.WS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-466,666
Closed -$147K – 178
2022
Q1 		$147K Hold
466,666
– – ﹤0.01% 174
2021
Q4 		$238K Hold
466,666
– – 0.01% 170
2021
Q3 		$273K Buy
+466,666
New +$342K 0.01% 175

Other funds holding AEON.WS

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
AC
Athos Capital Hong Kong $324M AUM 16.62% 1-Year Est. Return
Parallax Volatility Advisers
Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Empyrean Capital Partners's AEON.WS Position: Q2 2022 in Review

Empyrean Capital Partners sold out of AEON Biopharma Inc (AEON.WS) in Q2 2022, closing a stake of 466,666 shares — an estimated $147K sold.

Empyrean Capital Partners first reported a position in AEON.WS in Q3 2021 and held it in 3 quarters. The position peaked at $273K in Q3 2021. 52 funds tracked by Wall St. Rank hold AEON.WS as of Q2 2022.

  • Empyrean Capital Partners reported no remaining AEON Biopharma Inc position as of Q2 2022 after selling out during the quarter.
  • Empyrean Capital Partners sold 466,666 AEON Biopharma Inc shares in Q2 2022, an estimated $147K.
  • Empyrean Capital Partners first reported a position in AEON Biopharma Inc in Q3 2021 and held it in 3 quarters.
  • Empyrean Capital Partners's AEON Biopharma Inc position peaked at $273K in Q3 2021.
  • 52 funds tracked by Wall St. Rank held AEON Biopharma Inc as of Q2 2022.

Based on Empyrean Capital Partners's 13F filing for Q2 2022, filed 15 Aug 2022.